Physician

Anna H Zezon, M.D.

According to 2025 Medicare claims, Anna Zezon, M.D. (NPI: 1871866632) practices rheumatology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is ARTHRITIS & RHEUMATIC CARE (NPI: 1730642448) and primary practice location at 07666-4317. Zezon is affiliated with the Englewood Health ACO, LLC (ACO ID: A5653), participating under the MSSP model.

Zezon's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 166 traditional Medicare patients, billed 41,416 HCPCS/CPT codes, and received $584,073 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 536 prescription claims across 109 beneficiaries totaling $823,754 in drug costs, led by Enbrel Sureclick (Etanercept). Open Payments data shows 89 records totaling $1,363. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $15,021 to $584,073. Similarly, Part D prescription costs have moved sharply higher in recent years, from $47,070 to $823,754. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	110	279	$15,021
2016	N/R	N/R	N/R
2017	34	68	$5,457
2018	116	498	$35,730
2019	150	483	$35,630
2020	167	499	$33,797
2021	108	4,019	$172,742
2022	123	25,470	$381,884
2023	142	27,165	$401,787
2024	166	41,416	$584,073

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	115	891	$47,070
2016	26	74	$6,198
2017	21	42	$7,687
2018	107	388	$275,745
2019	146	784	$427,842
2020	178	760	$663,166
2021	108	415	$447,281
2022	102	451	$306,723
2023	104	524	$693,909
2024	109	536	$823,754

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	45	45	$136
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	133	388	$107
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	40	59	$76
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	43	137	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	136	410	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	56	1,680	$441,332
Teriparatide	Teriparatide	13	420	$35,085
Rasuvo	Methotrexate/Pf	15	1,092	$20,579
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	84	6,120	$4,219
Methotrexate	Methotrexate Sodium	53	3,746	$1,380

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	89	$1,363	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anna H. Zezon, M.D.?

Tedicare shows public-source Medicare data for Anna H. Zezon, M.D. (NPI 1871866632), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anna H. Zezon, M.D. have ACO affiliation data?

Anna H. Zezon, M.D. is shown with ACO affiliation data for Englewood Health ACO, LLC (MSSP, ACO ID A5653).

What billing organization is linked to Anna H. Zezon, M.D.?

Anna H. Zezon, M.D. is linked to ARTHRITIS & RHEUMATIC CARE (billing NPI 1730642448) in the available physician profile data.

Does Anna H. Zezon, M.D. have Open Payments data?

Anna H. Zezon, M.D. has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.